Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment followed the standard 12 month protocol. This was according to data from the DAPT (Dual Antiplatelet Therapy) Study, a key late-breaking clinical trial presented at the American Heart Association’s Scientific Sessions 2014 this week.
If you enjoy this content, please share it with a colleague
Covidien plc (NYSE: COV) announced results of the durability Iliac study and addition of the iliac indication for its EverFlex stent at the Vascular Interventional Advances (VIVA) 2014 conference.
Radcal Corporation announced the release of its first WiFi device, the Nugget, which will be unveiled at the 2014 RSNA trade show, along with the new Accu-Dose+ ion chamber based diagnostic meter, Accu-Gold, to replace the legacy dose meters.
Pierre Galvagni Silveira, M.D., Ph.D. enrolled the first two patients in the Gore Thoracoabdominal Aortic Aneurysm Clinical Study. This initial feasibility study of the Gore Excluder Thoracoabdominal Branch Endoprosthesis will assess the safety of the device implantation procedure in the treatment of abdominal aortic aneurysms encroaching on or involving visceral branch vessels.
VIVA Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announced late-breaking clinical trial results VIVA 14, an annual multidisciplinary vascular education conference hosted in Las Vegas.
